(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Kids get diseases like lupus, too. As researchers hunt better treatments, this camp brings joy - 2Italy Brings In New Measures In 2026 To Tackle Overtourism
- 3Vote In favor of Your Favored Shimmering Water
- 4NASA's make-or-break moon shot
- 5French rapper Gims placed under investigation for 'aggravated money laundering'
- Vacuum Cleaners That Are Not difficult To Use For Home
- Overlooked infertility care should be part of national health services, says WHO
- Instructions to Expand Your Advantages from an Open Record Reward
- U.K. blocks Kanye West from entering Britain to headline now canceled festival: What led to the ban
- 6 U.S. States for Climbing
- Dear Santa: I want Botox. Why cosmetic procedures are topping holiday wish lists.
- Birds Will Flock To Your Birdbath When You Plant These Two Flowers Around It
- Study reveals links between global food systems, obesity, and climate change
- Mars spacecraft images pinpoint comet 3I/ATLAS's path with 10x higher accuracy. This could help us protect Earth someday
